Virax Historical Cash Flow
| VRAX Stock | USD 1.81 0.03 1.63% |
Analysis of Virax Biolabs cash flow over time is an excellent tool to project Virax Biolabs Group future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Net Borrowings of 29.6 K or Begin Period Cash Flow of 9.8 M as it is a great indicator of Virax Biolabs ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Virax Biolabs Group latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Virax Biolabs Group is a good buy for the upcoming year.
Virax |
About Virax Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Virax balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Virax's non-liquid assets can be easily converted into cash.
Virax Biolabs Cash Flow Chart
Add Fundamental
Net Borrowings
The difference between the amount of new debt a company has taken on and the amount of debt it has paid off during a given period.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Most accounts from Virax Biolabs' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Virax Biolabs Group current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Virax Biolabs Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. At this time, Virax Biolabs' Begin Period Cash Flow is fairly stable compared to the past year. Other Cashflows From Financing Activities is likely to rise to about 1.9 M in 2024, despite the fact that Change To Inventory is likely to grow to (57.4 K).
Virax Biolabs cash flow statement Correlations
Click cells to compare fundamentals
Virax Biolabs Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Virax Stock Analysis
When running Virax Biolabs' price analysis, check to measure Virax Biolabs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virax Biolabs is operating at the current time. Most of Virax Biolabs' value examination focuses on studying past and present price action to predict the probability of Virax Biolabs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virax Biolabs' price. Additionally, you may evaluate how the addition of Virax Biolabs to your portfolios can decrease your overall portfolio volatility.